{"id":3560,"date":"2023-08-15T07:48:50","date_gmt":"2023-08-14T22:48:50","guid":{"rendered":"https:\/\/atlas.ncc.go.jp\/international_care\/ncc_today\/3560"},"modified":"2025-09-18T15:17:06","modified_gmt":"2025-09-18T06:17:06","slug":"%e8%a1%80%e6%b6%b2%e8%85%ab%e7%98%8d%e7%a7%91%e3%81%ab%e3%81%8a%e3%81%91%e3%82%8bCAR-T%e7%99%82%e6%b3%95","status":"publish","type":"imcs_blog","link":"https:\/\/atlas.ncc.go.jp\/en\/international_care\/ncc_today\/3560","title":{"rendered":"CAR-T therapy in Hematology"},"template":"","class_list":["post-3560","imcs_blog","type-imcs_blog","status-publish","hentry","en-US"],"acf":{"title_en":"CAR-T therapy in Hematology","from":{"jp":"Koji Izutsu","en":"Koji Izutsu"},"content":{"jp":"<p style=\"text-align: right;\">2023\/8\/15<\/p>\r\n<p><span>We have been conducting CAR-T therapy for B-cell lymphomas as clinical trials since 2017 and as a clinical practice since 2020. There are 3 CAR-T products for B-cell lymphomas and we conducted clinical development of these products in Japan. Currently, we are performing 3-5 cases of CAR-T therapy per months as clinical practice.<\/span><\/p>\r\n<p><span>Candidates for CAR-T for lymphoma include patients with third line diffuse large B-cell lymphoma (DLBCL); second line DLBCL who are eligible for transplant and CR duration of &lt;1 year or who are ineligible for transplant; third line follicular lymphoma. This new modality is expected to provide long-term benefit to at least a part of the patients for whom long-term survival could not be expected with conventional chemotherapy or hematopoietic stem cell transplantation.<\/span><\/p>","en":"<p style=\"text-align: right;\">2023\/8\/15<\/p>\r\n<p><span>We have been conducting CAR-T therapy for B-cell lymphomas as clinical trials since 2017 and as a clinical practice since 2020. There are 3 CAR-T products for B-cell lymphomas and we conducted clinical development of these products in Japan. Currently, we are performing 3-5 cases of CAR-T therapy per months as clinical practice.<\/span><\/p>\r\n<p><span>Candidates for CAR-T for lymphoma include patients with third line diffuse large B-cell lymphoma (DLBCL); second line DLBCL who are eligible for transplant and CR duration of &lt;1 year or who are ineligible for transplant; third line follicular lymphoma. This new modality is expected to provide long-term benefit to at least a part of the patients for whom long-term survival could not be expected with conventional chemotherapy or hematopoietic stem cell transplantation.<\/span><\/p>"},"thumbnail":2248,"show_in_detail":true,"show_in_topics":"","show_in_imcs_dept":["22"]},"_links":{"self":[{"href":"https:\/\/atlas.ncc.go.jp\/wp-json\/wp\/v2\/imcs_blog\/3560","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/atlas.ncc.go.jp\/wp-json\/wp\/v2\/imcs_blog"}],"about":[{"href":"https:\/\/atlas.ncc.go.jp\/wp-json\/wp\/v2\/types\/imcs_blog"}],"wp:attachment":[{"href":"https:\/\/atlas.ncc.go.jp\/wp-json\/wp\/v2\/media?parent=3560"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}